ISSN: 2167-7700
Chemotherapy: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

Chemotherapy: Too Much Of A Good Thing?

Gary L. Johanning*
Michael E. Keeling Center for Comparative Medicine and Research, Department of Veterinary Sciences, University of Texas, M.D. Anderson Cancer Center, Bastrop, USA
*Corresponding Author : Gary L. Johanning
Michael E. Keeling Center for Comparative Medicine and Research
Department of Veterinary Sciences
University of Texas
M.D. Anderson Cancer Center, Bastrop, USA
Tel: +512-332- 5211; +512-771-6932
Fax:
512-332-7375
E-mail: gljohann@mdanderson.org
Received October 31, 2012; Accepted November 01, 2012; Published November 04, 2012
Citation: Johanning GL (2012) Chemotherapy: Too Much of a Good Thing? Chemotherapy 1:e120. doi:10.4172/2167-7700.1000e120
Copyright: © 2012 Johanning GL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemotherapy: Open Access

Recent studies in Robert Gatenby’s laboratory at the Moffitt Cancer Center used computational models that were tested in cancer cells cultured in vitro, to provide support for the concept of “adaptive therapy” [1]. The idea for this type of therapy stems from a desire to capitalize on the extra metabolic strain that is placed on chemoresistant cancer cell populations, relative to their chemosensitive counterparts. Cancer chemotherapy drugs are normally given at the maximum tolerated dose (MTD), so that they have the greatest effect in killing cancer cells. But, this frequently leads to development of resistance to the chemotherapy. Adaptive therapy exploits a vulnerability of the chemo resistant cancer cell by providing a dose of drug that is less than the MTD, and instead, providing the minimum drug dose to maintain a stable tumor burden.
Two breast cancer cell lines were used in this study: MCF-7 and a cell line derived from MCF-7, MCF-7/Dox, which has acquired resistance to doxorubicin. The latter cell line has increased expression of the P-glycoprotein (PGP) membrane pump, which mediates active efflux of chemotherapeutic agents, including doxorubicin from the cytoplasm. An increased presence of PGP in the membrane results in decreased retention of a number of chemotherapeutic agents, leading to increased resistance to multiple other drugs or multidrug resistance (MDR). One tactic that has been somewhat effective in combating MDR is to treat with non-chemotherapy drugs, such as verapamil or cyclosporin A, which are substrates of PGP that can compete with the chemotherapy drug to slow down its efflux. But as pointed out by the authors, the amount of non-chemotherapy drug needed for effective competition is too toxic to be feasible, in the absence of other factors that limit development of chemoresistance.
They first found that when equal numbers of the two breast cancer cell lines were plated for 24 hr in culture media with a normal glucose concentration (2 g/L), and then switched to media with normal glucose, low glucose (0.5 g/L) or no glucose, the wild-type MCF-7 cells grew well in all three media. However, beginning at about 100 hr after exposure to the 3 levels of glucose, the MCF-7/Dox cells grown in lowor no-glucose media became much less viable than the wild-type MCF- 7 breast cancer cells.
Why the MCF-7/Dox cells did show decreased proliferation? The authors proposed that glucose restriction might place the MCF-7/Dox cells at a disadvantage, because they require more energy to maintain the PGP membrane pump. They tested this idea by growing co-cultures of the cells in the presence of 2-deoxyglucose, a competitor for glucose transporters, and additionally low doses of the non-chemotherapy drug, verapamil. Glucose restriction with 2-deoxyglucose increased the doubling time of both cell lines to about the same degree, but whereas addition of verapamil plus 2-deoxyglucose to the media had little additional effect on MCF-7 cell proliferation; this combination increased the doubling time two-fold in MCF-7/Dox cells. Thus, when energy was restricted in the MCF-7/Dox cells that over express PGP, and these cells were additionally subjected to the presence of a decoy molecule that increased the metabolic cost of drug resistance, the cells became less fit and growth rates slowed. In the presence of doxorubicin and high glucose, the MCF-7/Dox cells survived better than MCF-7, but either verapamil or low glucose decreased survival of the MCF-7/ Dox cells.
The requirement for extra glucose in the PGP-over expressing MCF-7/Dox cells was illustrated by the finding that the rate of glucose uptake by MCF-7/Dox cells was 4 times higher than the wild-type MCF-7 cells. The authors measured acid production and oxygen consumption rates of both cell lines, and made several assumptions related to oxygen consumption and ATP production to arrive at an estimate of energy production. Their results indicated that when cells were moved from low- to high-glucose conditions, the PGP mutant MCF-7/Dox cells switched to an anaerobic metabolism to a much greater extent than the parental MCF-7 cells. Under these conditions, MCF-7/Dox cells produced most of their energy by glycolysis, and the addition of oligomycin demonstrated that the maximum glycolytic potential of these doxorubicin-resistant cells is roughly three times higher that of than the parent cells. A take-home message of these studies is that the cell lines overexpressing PGP consume more energy than the parent breast cancer cells, which has also been shown in other studies using PGP mutant cell lines [2,3], and that the extra energy requirements are met primarily by anaerobic glycolysis.
One of the appealing aspects of this study is the computational model that was built to simulate the response of breast cancer patients to the glycolytic anti-metabolite and PGP substrate used in this study. Their model contained one sub-population of chemo sensitive and another of chemo resistant cancer cells, with one variable being the percentage of PGP-positive cells, initially present. The model incorporated the effects of optimum and energy-restricted conditions, with and without verapamil exposure on growth rates and drug sensitivity, and was based on their in vitro data using MCF-7 and MCF-7/Dox cell lines. Their model incorporated simulations of: 1) MTD; 2) MTD combined with chronic verapamil and 2-deoxyglucose; 3) adaptive therapy with an initial dose of half of the MTD and modification of the dose intensity by ±20%, to correct for tumor growth or reduction, respectively; and 4) AT combined with chronic verapamil and 2-deoxyglucose. They set 109 cells as the detection level for a tumor and 1012 cells as a lethal tumor burden. Their model confirmed the cell culture results that showed the important role of anaerobic glycolysis in supplying energy to the MCF- 7/Dox cells.
Their model also indicated that when PGP-positive MCF-7/Dox cells made up less than 10% of the initial cell population, the combination of adaptive therapy with both 2-deoxyglucose and verapamil led to increased survival, and a stabilization of tumor burden for a period longer than cells exposed to the MTD of doxorubicin. Adaptive therapy led to a two- to three-fold increase in survival, and the results were more impressive, with the combination of adaptive therapy plus the antimetabolite of glucose plus the alternative substrate of PGP. In this case, there was a four-fold increase in progression-free survival using their simulations. When the percentage of MCF-7/Dox cells was lowered to 5%, adaptive therapy combined with 2-deoxyglucose and verapamil increased patient survival to over 500 days, compared to a survival of 122 days for patients treated with the MTD of drug. In addition, their simulation suggested that survival was four-fold increased by adaptive therapy in the sub-population containing 5% MCF-7/Dox cells, and by ten-fold in this sub-population undergoing adaptive therapy with 2-deoxyglucose plus verapamil.
The work by this research group provides additional evidence that adaptive therapy has benefits in preventing or slowing the development of a doxorubicin-resistant population of cancer cells. Although only one drug was studied in one breast cancer cell line, a proof of principle was established that it may be possible to take advantage of a vulnerability in resistant cancer cells that relates to their greater requirement for cellular resources. In this case, it was a greater requirement for energy, but additional liabilities of drug-resistant cells may be uncovered, that would allow this approach to be expanded to control proliferation of chemo resistant cancer cell populations that form as a result of exposure to a variety of other chemotherapeutic agents. Under conditions where chemo resistant cells are vulnerable during periods where there is no exposure to the chemotherapy drug, the chemo sensitive cells would become competitive, leading to decreased proliferation of the chemo resistant population. The authors make the point that adaptive therapy is in many cases applied to a cancer patient inadvertently, when a dose of drug is toxic or not well tolerated, and during these drug-free periods chemo sensitive cells would be able to compete with the more susceptible chemo resistant sub-population and keep it suppressed.
A question that arises from this approach is whether use of the minimum drug intensity needed to maintain a stable tumor burden would permit metastasis, since treatment with the MTD of the drug may initially greatly lower the tumor burden, whereas this may not be the case with adaptive therapy. However, a recent study indicates that tumor chemoresistance goes hand-in-hand with increased metastatic propensity via a signaling network linking chemo resistance and metastasis [4]. Thus, the presence of a tumor that is largely chemo sensitive which would occur with adaptive therapy, might very well not promote metastasis.
References
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acute Lymphoblastic Leukemia
Disc Acute Megakaryocytic Leukemia
Disc Acute Myelomonocytic Leukemia
Disc Acute Myleoid Leukemia
Disc Adenocarcinoma pancreas
Disc Advances in Alternative Lung Cancer Treatment
Disc Aleukemic Leukemia
Disc Anti-Cancer Drug
Disc Apoptosis
Disc Bone Cancer Stages
Disc Bone Marrow Cancer Survival
Disc Brain Tumor Treatment
Disc Cancer Science
Disc Cancer Therapies
Disc Cancer initiation and progression
Disc Cancer therapy
Disc Carcinogenesis
Disc Chemo Resistance
Disc Chronic Lymphocytic Leukemia
Disc Chronic Myleloid Leukemia
Disc DNA damage
Disc Ductal adenocarcinoma
Disc Electro Chemotherapy
Disc Esophageal Cancer
Disc Feline Leukemia Complex
Disc Germ cell tumours
Disc Gynecological Cancers
Disc Hairy Cell Leukemia
Disc Kidney Cancer Prognosis
Disc Leukemia
Disc Leukemia Drugs
Disc Lung Tumor
Disc Lungs Cancer Cure
Disc Lymph Node Cancer
Disc Lymphoma Cancer
Disc Lymphoma Symptoms
Disc Lymphomatous polyposis
Disc Lymphosarcoma
Disc Mast Cell Leukemia
Disc Mutagenesis
Disc Oseophagus Cancer
Disc Ovarian Cancer and Prognosis
Disc Pancreatic Cancer
Disc Pediatric Leukemia
Disc Photo carcinogenesis
Disc Plasma Cell Leukemia
Disc Radiotherapy
Disc Sarcoma Cancer
Disc Spleen Cancer
Disc Squamous Cell Carcinoma
Disc Tumorigenesis
 
Recommended Journals
Disc Neuro-Oncology: Open Access
Disc Colorectal Cancer: Open Access
Disc Leukemia Journal
Disc Carcinogenesis Journal
Disc Cancer Journal
  View More»
 
Recommended Conferences
Disc 11th Asia-Pacific Oncologists Annual Meeting  
July 11-13, 2016 Kuala Lumpur, Malaysia
Disc 3rd World Congress on Women’s Health and Breast Cancer
October 03-05, 2016 London, UK
Disc 13th Cancer Therapy Summit  
October 17-19, 2016 Dubai, UAE
Disc Leukemia and Bone marrow Transplantation
November 10-12, 2016 Istanbul, Turkey
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11137
  [From(publication date):
December-2012 - Jun 25, 2016]
  Breakdown by view type
  HTML page views : 7409
  PDF downloads :3728
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version